These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 2027496)

  • 1. Treatment of Parkinson's disease with proglumide, a CCK antagonist.
    Piolti R; Appollonio I; Cocco E; Ferrarese C; Frattola L; Rovati L; Panerai AE
    Neurology; 1991 May; 41(5):749-50. PubMed ID: 2027496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cholecystokinin antagonist proglumide enhances the analgesic efficacy of morphine in humans with chronic benign pain.
    McCleane GJ
    Anesth Analg; 1998 Nov; 87(5):1117-20. PubMed ID: 9806692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide.
    Benedetti F; Amanzio M; Casadio C; Oliaro A; Maggi G
    Pain; 1997 Jun; 71(2):135-40. PubMed ID: 9211474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cholecystokinin antagonist proglumide enhances the analgesic effect of dihydrocodeine.
    McCleane GJ
    Clin J Pain; 2003; 19(3):200-1. PubMed ID: 12792559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proglumide, a cholecystokinin receptor antagonist, reduces neuroleptic action in Huntington's chorea.
    Piolti R; Appollonio I; Perego M; Pozzi C; Rovati L; Ferrarese C; Frattola L
    Eur Neurol; 1995; 35(6):344-8. PubMed ID: 8591802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the cholecystokinin antagonist proglumide possess antipsychotic activity?
    Innis RB; Bunney BS; Charney DS; Price LH; Glazer WM; Sternberg DE; Rubin AL; Heninger GR
    Psychiatry Res; 1986 May; 18(1):1-7. PubMed ID: 3737785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of proglumide, a putative CCK antagonist, on cerebral ischemia in gerbil.
    Xu C; Xue D; Su MC; Du LF; Gu X; Yang CL; Liu F
    Peptides; 1987; 8(5):769-72. PubMed ID: 3432123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Placebo-controlled, double-blind study of the effects of proglumide in the treatment of schizophrenia.
    Whiteford HA; Stedman TJ; Welham J; Csernansky JG; Pond SM
    J Clin Psychopharmacol; 1992 Oct; 12(5):337-40. PubMed ID: 1362205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cholecystokinin antagonist proglumide has an analgesic effect in chronic pancreatitis.
    McCleane GJ
    Pancreas; 2000 Oct; 21(3):324-5. PubMed ID: 11039479
    [No Abstract]   [Full Text] [Related]  

  • 10. Possible role of cholecystokinin in the development of acute pancreatitis in rats.
    Shinya H; Fujimura M
    Nihon Geka Hokan; 1989 Jan; 58(1):3-17. PubMed ID: 2802913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proglumide, a cholecystokinin antagonist, increases gastric emptying in rats.
    Shillabeer G; Davison JS
    Am J Physiol; 1987 Feb; 252(2 Pt 2):R353-60. PubMed ID: 3812772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia.
    Benedetti F
    Pain; 1996 Mar; 64(3):535-543. PubMed ID: 8783319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of systemic morphine analgesia in humans by proglumide, a cholecystokinin antagonist.
    Price DD; von der Gruen A; Miller J; Rafii A; Price C
    Anesth Analg; 1985 Aug; 64(8):801-6. PubMed ID: 4014744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxpentifylline in Parkinson's disease.
    Godwin-Austen RB; Twomey JA; Hanks G; Higgins J
    J Neurol Neurosurg Psychiatry; 1980 Apr; 43(4):360-4. PubMed ID: 7373336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
    Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
    Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
    Olanow CW; Alberts MJ
    Adv Neurol; 1987; 45():555-60. PubMed ID: 3548266
    [No Abstract]   [Full Text] [Related]  

  • 18. Adjunctive therapy with bromocriptine in Parkinson's disease.
    Temlett JA; Ming A; Saling M; Fritz VU; Blumenfeld A; Bilchik TR; Becker AL; Fourie PB; Reef HE
    S Afr Med J; 1990 Dec; 78(11):680-5. PubMed ID: 2251616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of mortality in pergolide-treated patients with Parkinson's disease.
    Sayler ME; Street JS; Bosomworth JC; Potvin JH; Kotsanos JG
    Neuroepidemiology; 1996; 15(1):26-32. PubMed ID: 8719046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bromocriptine (Parlodel) in the treatment of Parkinson's disease. Summary of 7 years' experience].
    Delwaide PJ; Schoenen J
    Rev Med Liege; 1983 May; 38(9):362-6. PubMed ID: 6867529
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.